Randomized, double-blind, parallel group, repeat dose pharmacokinetic and pharmacodynamic study of four doses of ATL-962 (40 mg, 80 mg, 120 mg 240 mg tid) in otherwise-healthy, obese volunteers

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN35772094

Enrollment

Registered

2005-09-16

Start date

2005-04-01

Completion date

Unknown

Last updated

2020-03-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity Nutritional, Metabolic, Endocrine Obesity

Interventions

ATL-962 40 mg, 80 mg, 120 mg or 240 mg three times a day for 14 days

Eligibility

Inclusion criteria

Inclusion criteria: Obese, otherwise-healthy, subjects, aged 18-40, with a body mass index between 30 kg/m2 and 45 kg/m2.

Exclusion criteria

Exclusion criteria: 1. Women who are pregnant or breast feeding 2. Any drug treatment within 2 weeks of commencement of dosing in this study

Design outcomes

Secondary

Measure	Time frame
Change from baseline in faecal fat excretion. Safety and tolerability	—

Primary

Measure	Time frame
Pharmacokinetics of the metabolites of ATL-962, namely ATL-1143 and ATL1277	—

Countries

United States of America

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026